| review article | Q7318358 |
| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00066-009-1936-5 |
| P698 | PubMed publication ID | 19506820 |
| P50 | author | Claus Rödel | Q64584868 |
| P2093 | author name string | Christian Weiss | |
| Franz Rödel | |||
| Gianni Capalbo | |||
| Friederike Marquardt | |||
| P2860 | cites work | Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer | Q24812583 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation | Q33868831 | ||
| Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 | ||
| Chemotherapy with preoperative radiotherapy in rectal cancer | Q34570877 | ||
| Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. | Q34571372 | ||
| Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy | Q36608809 | ||
| Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy | Q36614764 | ||
| An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation | Q36644150 | ||
| Integration of novel agents into combined-modality treatment for rectal cancer patients | Q36819451 | ||
| Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer | Q37118923 | ||
| Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 | ||
| Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer | Q40287803 | ||
| Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. | Q40415711 | ||
| Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. | Q43503018 | ||
| Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. | Q44234506 | ||
| Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. | Q46190706 | ||
| Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. | Q46365341 | ||
| Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092). | Q46659120 | ||
| Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer | Q46710475 | ||
| Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients | Q46781791 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. | Q49165929 | ||
| Adaptive RT in rectal cancer: superior to 3D-CRT? A simple question, a complex answer. | Q53441295 | ||
| Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. | Q54033425 | ||
| Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. | Q54598214 | ||
| Reduced Survival of Rectal Cancer Patients With Increased Tumor Epidermal Growth Factor Receptor Levels | Q56987716 | ||
| Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer | Q57095325 | ||
| Prognostic Significance of Vascular Endothelial Growth Factor and Cyclooxygenase-2 in Patients with Rectal Cancer Treated with Preoperative Radiotherapy | Q57770589 | ||
| The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis | Q57770590 | ||
| Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro | Q72181356 | ||
| In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody | Q73483324 | ||
| Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy | Q79899761 | ||
| Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy | Q80185978 | ||
| Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results | Q80324449 | ||
| Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer | Q81323824 | ||
| Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases | Q82669291 | ||
| Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation | Q83322147 | ||
| P433 | issue | 6 | |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| P304 | page(s) | 371-378 | |
| P577 | publication date | 2009-06-09 | |
| P1433 | published in | Strahlentherapie und Onkologie | Q15724604 |
| P1476 | title | Molecular targeted treatment and radiation therapy for rectal cancer | |
| P478 | volume | 185 |
| Q39912271 | Assay-based response evaluation in head and neck oncology: requirements for better decision making. |
| Q53275350 | Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. |
| Q33816412 | Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer |
| Q82419986 | Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells |
| Q37768039 | Combined-modality treatment for anal cancer: current strategies and future directions |
| Q39793772 | Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer |
| Q38237882 | Early and late toxicity of radiotherapy for rectal cancer |
| Q53211347 | Erlotinib-induced rash spares previously irradiated skin. |
| Q33997798 | Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy |
| Q84972389 | Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer |
| Q37817000 | Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial? |
| Q50062237 | Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial |
| Q33834316 | Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer |
| Q37272825 | Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial |
| Q38064748 | Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? |
| Q39602064 | Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells |
| Q37676970 | Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function |
| Q39602655 | Omega-3 fatty acid supplementation in cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells? |
| Q39744649 | Overexpression of caveolin-1 in lymphoblastoid TK6 cells enhances proliferation after irradiation with clinically relevant doses. |
| Q35083126 | Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets |
| Q59616759 | Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer |
| Q36368072 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma |
| Q50967527 | Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? |
| Q53724796 | Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials. |
| Q37743143 | The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma |
| Q35996651 | The current state of targeted agents in rectal cancer |
| Q46420172 | Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer |
| Q54493763 | [Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma]. |
Search more.